MedPath

Effect of Real Time Continuous Glucose Monitoring System on the Management of Type 2 Diabetes

Not Applicable
Completed
Conditions
Type 2 Diabetes
Interventions
Device: Guardian RT
Behavioral: Education about the self monitoring blood glucose
Registration Number
NCT00536549
Lead Sponsor
Korea University
Brief Summary

The purpose of this study is to determine whether the Guardian Continuous Glucose Monitoring System in the home setting is more useful than frequent self blood glucose monitoring with a view to modifying patient's diet and exercise habits or improvement self disease control efforts and at last glycemic control in patients with type 2 diabetes

Detailed Description

In diabetes management, compliance, disease awareness and empowerment of the patient play an important role and the immediate feedback on the effects of diet and exercise that the self monitoring blood glucose (SMBG) may provide, could enhance patient empowerment. Increased use of SMBG has been shown to be associated with improved medication compliance and better metabolic control by several studies. However, because of many factors, including pain and inconvenience, many diabetic patients do not accept frequent fingersticks for self blood glucose monitoring (SBGM) levels. In addition, the SBGM result gives the data for only a few seconds, without any information on glucose trends.

So we need new glucose monitoring method that could reflect glucose trends and glycemic excursion continuously because glucose monitoring still remains the cornerstone of evaluating the efficacy of therapy and motivating self disease control in subjects with diabetes.

Few studies have examined the effects of real time continuous glucose monitoring system targeting type 2 diabetes. So our goal is to determine whether the Guardian Continuous Glucose Monitoring System in the home setting is more useful than frequent self blood glucose monitoring with a view to modifying patient's diet and exercise habits or improvement self disease control efforts and at last glycemic control in patients with type 2 diabetes

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
127
Inclusion Criteria
  • Type 2 diabetes
  • Group 1: HbA1c < 8% with a stable insulin or oral hypoglycemic agents (OHA) regimen for the prior 2 months with no plans to switch modality of insulin or OHA administration during the next 3months.
  • Group 2: HbA1c >= 8% and the fasting blood glucose must be < 130 at the same time with a stable insulin or oral hypoglycemic agents (OHA) regimen for the prior 2 months with no plans to switch modality of insulin or OHA administration during the next 3months
Exclusion Criteria
  • Use of corticosteroids or hormone therapy within the last 6 months
  • Presence of another chronic illness

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
AGuardian RTGuardina RT monitoring
BEducation about the self monitoring blood glucose-
Primary Outcome Measures
NameTimeMethod
HbA1c, fasting blood glucose level, weight change, blood pressure in the morning, lipid profilesbasline, 12weeks later
Secondary Outcome Measures
NameTimeMethod
three day diary meals and seven day physical activity diarybasline, 12 weeks later

Trial Locations

Locations (1)

Division of Endocrinology and Metabolism, Department of Internal Medicine,Korea University College of Medicine

🇰🇷

Seoul, Korea, Republic of

© Copyright 2025. All Rights Reserved by MedPath